Insider Selling: Bicycle Therapeutics (NASDAQ:BCYC) CEO Sells 2,263 Shares of Stock

Key Points

• Kevin Lee, the CEO of Bicycle Therapeutics, sold 2,263 shares at an average price of $8.40, bringing the total transaction value to $19,009.20, which resulted in a 0.47% decrease in his shareholding.
• The company's stock has a 52-week range of $6.10 to $28.67, and recent trading on Monday saw shares fall to $8.23.
• Despite missing earnings expectations with a reported EPS of ($1.14), Bicycle Therapeutics has a market cap of approximately $570.42 million and maintains a consensus rating of "Moderate Buy" among analysts.

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC - Get Free Report) CEO Kevin Lee sold 2,263 shares of Bicycle Therapeutics stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $8.40, for a total value of $19,009.20. Following the completion of the sale, the chief executive officer directly owned 478,541 shares of the company's stock, valued at approximately $4,019,744.40. The trade was a 0.47% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Kevin Lee also recently made the following trade(s):

• On Friday, October 3rd, Kevin Lee sold 3,231 shares of Bicycle Therapeutics stock. The shares were sold at an average price of $8.41, for a total value of $27,172.71.

Bicycle Therapeutics Stock Performance

Shares of Bicycle Therapeutics stock traded down $0.14 during trading hours on Monday, hitting $8.23. The company's stock had a trading volume of 260,910 shares, compared to its average volume of 312,837. The business has a 50 day moving average price of $7.44 and a two-hundred day moving average price of $7.80. Bicycle Therapeutics PLC Sponsored ADR has a 12-month low of $6.10 and a 12-month high of $28.67. The company has a market cap of $570.42 million, a PE ratio of -2.34 and a beta of 1.47.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last posted its earnings results on Friday, August 8th. The company reported ($1.14) EPS for the quarter, missing analysts' consensus estimates of ($0.95) by ($0.19). The firm had revenue of $2.90 million during the quarter, compared to analysts' expectations of $9.43 million. Bicycle Therapeutics had a negative return on equity of 32.43% and a negative net margin of 1,257.00%. As a group, research analysts anticipate that Bicycle Therapeutics PLC Sponsored ADR will post -3.06 earnings per share for the current year.

Hedge Funds Weigh In On Bicycle Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Acadian Asset Management LLC acquired a new position in shares of Bicycle Therapeutics in the 1st quarter valued at approximately $1,065,000. Principal Financial Group Inc. grew its holdings in shares of Bicycle Therapeutics by 55.3% during the first quarter. Principal Financial Group Inc. now owns 631,260 shares of the company's stock valued at $5,359,000 after purchasing an additional 224,790 shares during the last quarter. Exchange Traded Concepts LLC boosted its stake in Bicycle Therapeutics by 90.3% during the 1st quarter. Exchange Traded Concepts LLC now owns 12,764 shares of the company's stock valued at $108,000 after purchasing an additional 6,057 shares during the period. Goldman Sachs Group Inc. acquired a new position in Bicycle Therapeutics during the 1st quarter valued at about $214,000. Finally, Westfield Capital Management Co. LP boosted its stake in Bicycle Therapeutics by 1.8% during the 1st quarter. Westfield Capital Management Co. LP now owns 2,657,305 shares of the company's stock valued at $22,561,000 after purchasing an additional 46,968 shares during the period. Institutional investors and hedge funds own 86.15% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on BCYC. Weiss Ratings reiterated a "sell (e+)" rating on shares of Bicycle Therapeutics in a report on Saturday, September 27th. Oppenheimer reaffirmed an "outperform" rating and set a $44.00 price target (down from $48.00) on shares of Bicycle Therapeutics in a research report on Monday, August 11th. JMP Securities cut their target price on Bicycle Therapeutics from $22.00 to $10.00 and set a "market outperform" rating on the stock in a research report on Tuesday, August 12th. Morgan Stanley reduced their price objective on Bicycle Therapeutics from $17.00 to $13.00 and set an "equal weight" rating for the company in a research note on Tuesday, August 12th. Finally, Royal Bank Of Canada set a $27.00 target price on shares of Bicycle Therapeutics and gave the company an "outperform" rating in a report on Monday, August 11th. Six investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $22.22.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.